Project Grant R01HL180806
Award Date 8/1/26
Completion Date 4/30/28
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- The National Heart, Lung, and Blood Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Washington University $768,128 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to mechanistically evaluate the role of oscillatory shear stress in deep vein thrombosis prevention. The recipient will conduct in vitro, in vivo, and human model studies to determine whether restoration of oscillatory shear stress in veins...
- The National Heart Lung and Blood Institute (NHLBI), a component of the Department of Health and Human Services National Institutes of Health, awarded $743,131 to the University of Wisconsin - Madison on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate regulatory mechanisms of the vessel wall in deep vein thrombosis. The research addresses thrombospondin-1 (TSP1), a matricellular protein upregulated in endothelial cells during DVT. The project tests...
- The National Heart Lung and Blood Institute awarded The Johns Hopkins University $175,874 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a prospective, three-center cohort study investigating clinical risk factors and biomarkers for recurrent venous thromboembolism in children with cardiac disease. The research addresses the elevated risk of recurrent VTE events—including deep vein thrombosis and pulmonary embolism—in children with congenital and...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $381,864 on September 16, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sociodemographic and clinical factors associated with venous thromboembolism (VTE) outcomes and secondary anticoagulation use in children. The project analyzes data from a multicenter prospective cohort study of pediatric VTE patients to address the impact of...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $2.815 million on September 24, 2025, under CFDA 93.837 (Cardiovascular Diseases Research) to conduct proteomic and genomic discovery of molecular targets linked to atrial cardiopathy-related cardiovascular outcomes. The award funds research using proteomics and genomic methods across primary and secondary prevention populations to identify novel proteins that may serve as causal risk factors for atrial...
- The National Heart, Lung and Blood Institute awarded the University of Washington $1,601,223 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to combine large-scale experiments and computational modeling to dissect how variants in the F9 gene affect coagulation factor IX (FIX) secretion, carboxylation, activation, and disease pathogenesis. The research addresses the clinical challenge of interpreting variants of uncertain significance (VUS) in hemophilia B...
- The National Heart, Lung, and Blood Institute awarded Trustees of Boston University $1.668 million on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct the STOP-SCD-VTE study examining anticoagulation outcomes and practice patterns for patients with sickle cell disease and venous thromboembolism. The research uses three real-world registries—TriNetX (non-SCD-specific), GRNDAD (Globin Regional Data and Discovery), and the ASH Research Collaborative...
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $1.6 million under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate GA12-dependent mechanisms of basal and regulated endothelial cell von Willebrand factor (VWF) secretion. This is a Project Grant (R01HL186410). The research addresses microvascular thrombotic occlusions in inflammatory conditions such as sepsis and sickle cell disease, where elevated VWF plasma levels...
- The National Heart Lung and Blood Institute awarded Regents of the University of Michigan $771,350 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an endovascular vortex ultrasound thrombolysis system for treatment of pulmonary embolism. The project will design, fabricate, and characterize a vortex ultrasound transducer integrated into a 9-French catheter to achieve rapid (under 30 minutes) and safe thrombolysis with minimal lytic agent and...
- The National Heart, Lung, and Blood Institute awarded The University of Chicago $642,477 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a targeted quality improvement trial improving post-discharge venous thromboembolism (VTE) chemoprophylaxis following abdominal and pelvic cancer surgery. The trial addresses the gap between clinical evidence and practice adoption. Randomized trials have demonstrated that chemoprophylaxis extending beyond...